Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Atriva Therapeutics GmbH holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This activity is being reviewed by a lone distinct examiner and is located within a lone distinct art unit. This indicates a concentrated focus for the company's current biotechnology-related patent applications. The company's work in the Biotechnology & Pharmaceuticals field suggests a specialized research focus that is currently being tested through a single examination channel.
The busiest examiner, NESTOR, DONNA MICHELLE, is currently handling 1 busiest examiner pending office action. This figure represents the total number of pending office actions for the company. For practitioners, this means that the prosecution strategy is tied to a lone examiner's interpretation of the claims. The fact that there is a lone distinct art unit involved suggests that the company's active applications are confined to a specific technical area, making the outcome of the 1 pending office action a significant event for the company's intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999185 | MEK-INHIBITORS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | NESTOR, DONNA MICHELLE | 89d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999185 | MEK-INHIBITORS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | NESTOR, DONNA MICHELLE | 89d overdue |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17999185 | MEK-INHIBITORS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | NESTOR, DONNA MICHELLE | 1627 | §103§112Other | Non-Final OA | 89d overdue | Pending | Nov 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial